Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging technique could help doctors predict cancer treatment response

NCT ID NCT01235052

Completed Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a PET scan using a tracer called FMISO can measure oxygen levels (hypoxia) in head and neck cancers. Sixteen patients received the scan before starting radiotherapy. The goal was to see if the amount of hypoxia seen on the scan could predict how well the cancer responded two years later. The results were not used to change treatment, but to see if this imaging method could be useful in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
18F-FMISO (a radioactive tracer used in PET scans)
What this could lead to
If successful, this could help doctors better predict how head and neck cancers will respond to radiotherapy, potentially guiding more personalized treatment plans.
What could go wrong
This was a very small study (16 people) and only looked at whether the scan could predict outcomes—it did not test a new treatment. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer head and neck neoplasm Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF HEAD AND NECK HEAD AND NECK NEOPLASMS

Contacts and locations

Locations

  • CHU de Bordeaux - Hôpital Pellegrin

    Bordeaux, 33 076, France

  • Hôpital Robert Picqué

    Villenave-d'Ornon, 33882, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.